Research Study

Biorest Liposomal Alendronate Administration for Diabetic Patients Undergoing Drug-Eluting Stent Percutaneous Coronary Intervention
Principal Investigator 
David Wood

Overview

Body Locations and Systems 
Diabetic Heart Disease
Disorders and Conditions 
Diabetes Complications
ClinicalTrials.gov# 
NCT02645799
Status 
Recruiting
Study Start/End 
Jun 27, 2017 to Dec 31, 2018
Locations 
Vancouver General Hospital
Name/Title 
Naomi Uchida
Phone 
604-875-4521
Email Address 
naomi.uchida@vch.ca
Purpose of Study 

The main objective of this study is to assess the safety, efficacy and dose response of LABR-312 administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent in reducing restenosis as measured by Optical Coherence Tomography (OCT) at 9 months post procedure in patients with diabetes mellitus (DM).

Administration of LABR-312 at the time of PCI will reduce restenosis compared with placebo as assessed by the OCT endpoint of % neointimal hyperplasia (%NIH) volume at 9 months in patients with DM.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.